Study of Alendronate to Prevent and Treat Osteoporosis in Cystic Fibrosis Patients
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine efficacy of 70 mg alendronate once weekly
compared to placebo. This will be measured by percent changes in lumbar spine(LS) bone
mineral density(BMD) in adult cystic fibrosis(CF)patients after one year of treatment. The
investigators hypothesize that in adult CF patients with osteopenia or osteoporosis,
alendronate 70 mg once weekly will produce a mean increase from baseline in lumbar spine BMD
that is greater than that observed with placebo at 12 months.